Skip to main content

Aurinia Pharm Ord(AUPH-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low9.40
Day High9.77
Open:9.62
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

Download Premium PDFRefinitiv. Trademark. Data is Just the Beginning.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Download Premium PDFStockCalc

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Download Premium PDFValueEngine

Press & news

Latest News

More Stories
MKT Capital Issues Statement Regarding Aurinia’s Disappointing First Quarter 2023 Financial Results
Business Wire - Fri May 5, 10:00AM CDT
Business Wire
Fri May 5, 10:00AM CDT
MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial ownership of approximately 4.2% of Aurinia’s outstanding...
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
Business Wire - Thu May 4, 5:00AM CDT
Business Wire
Thu May 4, 5:00AM CDT
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars.
ISS Recommends Aurinia Shareholders Vote Against the Company’s Named Executive Officers’ Compensation
Business Wire - Wed May 3, 1:20PM CDT
Business Wire
Wed May 3, 1:20PM CDT
MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial ownership of approximately 4.2% of Aurinia’s outstanding...

Latest Articles

Wednesday’s analyst upgrades and downgrades
Friday’s analyst upgrades and downgrades
Short sales on the TSX: What bearish investors are betting against
Tuesday’s analyst upgrades and downgrades
Tuesday’s analyst upgrades and downgrades
Wednesday’s analyst upgrades and downgrades
Market movers: Stocks that saw action on Monday - and why
Small cap stocks to watch on Thursday
Aurinia Pharmaceuticals stock surges on positive clinical results for lupus drug
Friday’s Insider Report: Companies insiders are buying and selling
me and my money
Millennial investor mindful of Indigenous rights and climate change
Montreal cancer drug developer Repare raises $68-million

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.